Previous Close | 9.59 |
1-Year Change | -10.87% |
6-Months Change | -1.34% |
3-Months Change | -18.03% |
Moving Avg (50d) | 10.8906 |
Moving Avg (200d) | 11.0052 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.79B |
Beta (3-Years) | 1.07 |
Revenue Growth (ttm) | 15.18% |
Net Profit Margin (ttm) | -46.62% |
Return On Assets (ttm) | -22.72% |
EPS (ttm) | -0.59 |
PE Ratio (ttm) | -16.25 |
Dividend Yield | % |
Asset Description: | Amicus Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
9.782 | 10.07 | 10.261 | 10.549 | 11.029 | 11.508 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Amicus Therapeutics is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners... Wikipedia